These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26104049)

  • 1. Changes in Warfarin Sensitivity During Decompensated Heart Failure and Chronic Obstructive Pulmonary Disease.
    del Campo M; Roberts G
    Ann Pharmacother; 2015 Sep; 49(9):962-8. PubMed ID: 26104049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of heart failure exacerbations on anticoagulation: a prospective, observational, pilot cohort study.
    Ripley TL; Harrison D; Germany RE; Adamson PB
    Clin Ther; 2010 Mar; 32(3):506-14. PubMed ID: 20399987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive Care Unit Admission and Survival among Older Patients with Chronic Obstructive Pulmonary Disease, Heart Failure, or Myocardial Infarction.
    Valley TS; Sjoding MW; Ryan AM; Iwashyna TJ; Cooke CR
    Ann Am Thorac Soc; 2017 Jun; 14(6):943-951. PubMed ID: 28208030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with non-fatal heart failure and atrial fibrillation or flutter within the first 30 days post COPD exacerbation: a nested case-control study.
    Graul EL; Nordon C; Rhodes K; Menon S; Al Ammouri M; Kallis C; Ioannides AE; Whittaker HR; Peters NS; Quint JK
    BMC Pulm Med; 2024 May; 24(1):221. PubMed ID: 38704538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
    Magnani G; Giugliano RP; Ruff CT; Murphy SA; Nordio F; Metra M; Moccetti T; Mitrovic V; Shi M; Mercuri M; Antman EM; Braunwald E
    Eur J Heart Fail; 2016 Sep; 18(9):1153-61. PubMed ID: 27349698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial).
    Lee TC; Qian M; Lip GYH; Di Tullio MR; Graham S; Mann DL; Nakanishi K; Teerlink JR; Freudenberger RS; Sacco RL; Mohr JP; Labovitz AJ; Ponikowski P; Lok DJ; Estol C; Anker SD; Pullicino PM; Buchsbaum R; Levin B; Thompson JLP; Homma S; Ye S;
    Am J Cardiol; 2018 Sep; 122(5):821-827. PubMed ID: 30037426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.
    Kubota Y; Asai K; Furuse E; Nakamura S; Murai K; Tsukada YT; Shimizu W
    Int J Chron Obstruct Pulmon Dis; 2015; 10():515-23. PubMed ID: 25784798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Medication Intensity and Stages of Airflow Limitation With the Risk of Hospitalization or Death in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease.
    Lawson CA; Mamas MA; Jones PW; Teece L; McCann G; Khunti K; Kadam UT
    JAMA Netw Open; 2018 Dec; 1(8):e185489. PubMed ID: 30646293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: A sub-analysis of GISSI-HF trial.
    Rossi A; Inciardi RM; Rossi A; Temporelli PL; Lucci D; Gonzini L; Marchioli R; Nicolosi GL; Tavazzi L;
    Pulm Pharmacol Ther; 2017 Jun; 44():16-23. PubMed ID: 28263812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does heart failure exacerbation increase response to warfarin? A critical review of the literature.
    Self TH; Reaves AB; Oliphant CS; Sands C
    Curr Med Res Opin; 2006 Nov; 22(11):2089-94. PubMed ID: 17076968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry.
    Canepa M; Straburzynska-Migaj E; Drozdz J; Fernandez-Vivancos C; Pinilla JMG; Nyolczas N; Temporelli PL; Mebazaa A; Lainscak M; Laroche C; Maggioni AP; Piepoli MF; Coats AJS; Ferrari R; Tavazzi L;
    Eur J Heart Fail; 2018 Jan; 20(1):100-110. PubMed ID: 28949063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.
    Bussey HI; Bussey M; Bussey-Smith KL; Frei CR
    Pharmacotherapy; 2013 Nov; 33(11):1136-46. PubMed ID: 24038412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine learning for the development of diagnostic models of decompensated heart failure or exacerbation of chronic obstructive pulmonary disease.
    Gálvez-Barrón C; Pérez-López C; Villar-Álvarez F; Ribas J; Formiga F; Chivite D; Boixeda R; Iborra C; Rodríguez-Molinero A
    Sci Rep; 2023 Aug; 13(1):12709. PubMed ID: 37543661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COPD patients hospitalized with exacerbations have greater cognitive impairment than patients hospitalized with decompensated heart failure.
    Bajaj MK; Burrage DR; Tappouni A; Dodd JW; Jones PW; Baker EH
    Clin Interv Aging; 2019; 14():1-8. PubMed ID: 30587948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009.
    Staszewsky L; Cortesi L; Tettamanti M; Dal Bo GA; Fortino I; Bortolotti A; Merlino L; Latini R; Roncaglioni MC; Baviera M
    Eur J Heart Fail; 2016 Jul; 18(7):840-8. PubMed ID: 27098360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10.
    Gunther KE; Conway G; Leibach L; Crowther MA
    Thromb Res; 2004; 113(3-4):205-9. PubMed ID: 15140584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of care for atrial fibrillation among patients hospitalized for heart failure.
    Piccini JP; Hernandez AF; Zhao X; Patel MR; Lewis WR; Peterson ED; Fonarow GC;
    J Am Coll Cardiol; 2009 Sep; 54(14):1280-9. PubMed ID: 19778670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute pulmonary embolism during warfarin therapy and long-term risk of recurrent fatal pulmonary embolism.
    Moutzouris JP; Ng AC; Chow V; Chung T; Curnow J; Kritharides L
    Thromb Haemost; 2013 Sep; 110(3):523-33. PubMed ID: 23740364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of chronic obstructive pulmonary disease on exercise ventilatory efficiency in heart failure.
    Apostolo A; Laveneziana P; Palange P; Agalbato C; Molle R; Popovic D; Bussotti M; Internullo M; Sciomer S; Bonini M; Alencar MC; Godinas L; Arbex F; Garcia G; Neder JA; Agostoni P
    Int J Cardiol; 2015; 189():134-40. PubMed ID: 25889444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.